Helicobacter pylori Eradication in Drug-related Peptic Ulcer.
Moon Kyung JooPublished in: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi (2021)
Non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin are the most frequently prescribed drugs worldwide, and their long-term use often leads to peptic ulcers (PUs) along with serious complications, such as bleeding and perforation. Helicobacter pylori (H. pylori) infection is a significant risk factor for developing NSAID-related PU and ulcer bleeding during long-term aspirin use. In a revised version of the Clinical Guidelines for Drug-induced Peptic Ulcer, two statements regarding H. pylori eradication are recommended. 1) Patients scheduled for long-term NSAID therapy should be tested and treated for H. pylori infection to prevent PU and its complications. 2) Patients with a history of PU receiving long-term low-dose aspirin (LDA) therapy should undergo treatment for H. pylori infection to prevent PU and its complications. On the other hand, unlike NSAID-naïve patients, the preventive effects of H. pylori eradication in chronic NSAID users are unclear. In addition, anti-ulcer drugs, such as proton pump inhibitors, may be necessary for maintenance therapy after H. pylori eradication in a subset of long-term LDA users, particularly if the patients are taking concomitant antiplatelet agents or anticoagulants.
Keyphrases
- helicobacter pylori
- low dose
- helicobacter pylori infection
- drug induced
- end stage renal disease
- anti inflammatory drugs
- newly diagnosed
- ejection fraction
- chronic kidney disease
- liver injury
- prognostic factors
- peritoneal dialysis
- stem cells
- atrial fibrillation
- emergency department
- patient reported outcomes
- cardiovascular disease
- bone marrow
- antiplatelet therapy
- clinical practice
- mesenchymal stem cells
- replacement therapy